Molecular Partners AG
SIX:MOLN
Molecular Partners AG
Intangible Assets
Molecular Partners AG
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Intangible Assets
CHf5k
|
CAGR 3-Years
-74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Intangible Assets
CHf371k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
2%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Intangible Assets
CHf29.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
107%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Intangible Assets
CHf18.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Intangible Assets
CHf30.6m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Intangible Assets?
Intangible Assets
5k
CHF
Based on the financial report for Sep 30, 2025, Molecular Partners AG's Intangible Assets amounts to 5k CHF.
What is Molecular Partners AG's Intangible Assets growth rate?
Intangible Assets CAGR 3Y
-74%
Over the last year, the Intangible Assets growth was -94%. The average annual Intangible Assets growth rates for Molecular Partners AG have been -74% over the past three years .
